Clinical trials: IL6
Endometrial Cancer, Obesity
Adipocytokines in Endometrial Cancer
The number of women diagnosed with uterine cancer continues to rise each year. Since the early 1990s, there has been almost 55% rise in the United Kingdom (UK). 34% of endometrial cancer can be attributed to obesity.
- Trial name
- NCT04697264
- Testing
- Blood and tissue sample collection from patients
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Surrey
Subarachnoid Hemorrhage, Stroke
Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH
This study compares the bioavailability of IV and PO acetaminophen in both blood and the cerebrospinal fluid (CSF) of patients following subarachnoid hemorrhage.
- Trial name
- aSAH (NCT02549716)
- Testing
- IV acetaminophen, Oral acetaminophen
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Milton S. Hershey Medical Center
Indolent Systemic Mastocytosis
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
Background: Mast cells help the body fight disease and heal wounds. People with indolent systemic mastocytosis (ISM) make too many mast cells. This causes pain, tiredness, digestive problems, and other symptoms.
- Trial name
- NCT03770273
- Testing
- sarilumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
The purpose of this study is to evaluate safety and effectiveness of CNTO 328 (siltuximab) when it is administered together with velcade-melphalan-prednisone (VMP) in comparison with VMP alone in participants with multiple…
- Trial name
- NCT00911859
- Testing
- Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib)
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 118 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Kidney Diseases, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial.
- Trial name
- RESCUE (NCT03926117)
- Testing
- Ziltivekimab
- Where
- 49 sites in United States
- Volunteers
- 264 people
- Sponsor
- Novo Nordisk A/S
Arthritis, Rheumatoid
A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate the effectiveness and safety of subcutaneous (under the skin) administration of anti-interleukin-6 monoclonal antibody (CNTO 136) in reducing signs and symptoms of participants with active…
- Trial name
- NCT00718718
- Testing
- CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg
- Where
- 38 sites in United States, Hungary and 5 more
- Volunteers
- 187 people
- Sponsor
- Centocor, Inc.
Chronic Kidney Diseases, Chronic Kidney Insufficiency
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease…
- Conditions
- Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency
- Trial name
- TRANQUILITY (NCT06362759)
- Testing
- TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG
- Where
- 38 sites in United States
- Volunteers
- 143 people
- Sponsor
- Tourmaline Bio, Inc., a Novartis Company
Chronic Kidney Disease, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.
The purpose of this research study is to compare the safety and effectiveness of 2 different doses of a study drug called ziltivekimab to placebo (an inactive substance) in reducing inflammation and improving some of the bad…
- Conditions
- Chronic Kidney Disease, Inflammation, Cardiovascular Risk
- Trial name
- RESCUE-2 (NCT04626505)
- Testing
- Ziltivekimab
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
COVID-19
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.
- Trial name
- NCT04315298
- Testing
- Sarilumab
- Where
- 62 sites in United States
- Volunteers
- 1,912 people
- Sponsor
- Regeneron Pharmaceuticals
Perioperative Inflammatory Response
Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery
The purpose of the present study is to quantify the degree of modulation, if any, in the perioperative inflammatory response associated with statins use.
- Trial name
- NCT00656292
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Mayo Clinic
Oral Lichen Planus
A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
A phase 2 randomized, placebo-controlled, double-blind trial of a two week course of curcuminoids in oral lichen planus will be conducted.
- Trial name
- NCT00525421
- Testing
- Curcuminoids
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nita Chainani Wu
Schizophrenia
An Open-Label Trial of Tocilizumab in Schizophrenia
This study is a Phase 1 clinical trail to determine the safety, tolerability, and efficacy of Tocilizumab (Actemra) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia.
- Trial name
- NCT01696929
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Brian Miller
COVID-19
Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)
This is a single center, randomized, double-blind, placebo-controlled, exploratory phase II study enrolling 60 patients. We propose the administration of a blinded dose of an investigational product (IP) (clazakizumab or placebo…
- Trial name
- NCT04348500
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cedars-Sinai Medical Center
Autoimmune Diseases, Systemic Inflammatory Process
Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish…
- Conditions
- Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis
- Trial name
- VITAL (NCT01351805)
- Testing
- Fish Oil, Vitamin D
- Where
- United States
- Volunteers
- 25,871 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Melanoma
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
This is a Phase II, open-label, single arm study. The study will consist of an assessment of the safety and tolerability of tocilizumab administered concurrently at 4 mg/kg every 6 weeks for 5 doses in combination with ipilimumab…
- Trial name
- NCT03999749
- Testing
- Ipilimumab, Nivolumab, Tocilizumab
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- NYU Langone Health
Non-small Cell Lung Cancer
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
The purpose of this study was to evaluate the major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR of…
- Trial name
- CANOPY-N (NCT03968419)
- Testing
- Canakinumab, Pembrolizumab
- Where
- 29 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Obesity, Diabetes
Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults
The investigators want to determine if the benefits of weight loss outweigh the potential risk in a group of older adults. The investigators will test the hypothesis that changes in diet composition alone or in conjunction with…
- Conditions
- Obesity, Diabetes, Hypertension, Hyperlipidemia
- Trial name
- CROSSROADS (NCT00955903)
- Testing
- Exercise, Reduced Calorie Diet, Weight Maintenance Diet
- Where
- United States
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
The purpose of this study is to evaluate the safety and efficacy of sirukumab as a single therapy in Japanese patients with moderately to severely active rheumatoid arthritis (RA) who have not responded to treatment with…
- Trial name
- NCT01689532
- Testing
- Sirukumab 100 mg, Sirukumab 50 mg
- Where
- 17 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Janssen Pharmaceutical K.K.
Glucocorticosteroid Refractory Acute GVHD
Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)
The purpose of this study is to determine if Tocilizumab is a safe and effective treatment for steroid-refractory acute graft versus host disease.
- Trial name
- NCT01757197
- Testing
- Toclizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
Total Knee Arthroplasty
Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty
One postoperative complication following unilateral or bilateral total knee arthroplasty is thrombosis (blood clot formation). In this prospective, double-blinded randomized controlled clinical trial, researchers are…
- Trial name
- NCT01815918
- Testing
- Hydrocortisone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hospital for Special Surgery, New York